Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to $248000.0.

  • AVITA Medical's Cash from Financing Activities fell 7571.01% to $248000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $14.9 million, marking a year-over-year increase of 32576.97%. This contributed to the annual value of $14.9 million for FY2025, which is 32576.97% up from last year.
  • As of Q4 2025, AVITA Medical's Cash from Financing Activities stood at $248000.0, which was down 7571.01% from $13.8 million recorded in Q3 2025.
  • AVITA Medical's 5-year Cash from Financing Activities high stood at $64.0 million for Q1 2021, and its period low was -$64.1 million during Q2 2022.
  • For the 5-year period, AVITA Medical's Cash from Financing Activities averaged around $3.3 million, with its median value being $579500.0 (2023).
  • Per our database at Business Quant, AVITA Medical's Cash from Financing Activities soared by 9840461.54% in 2021 and then tumbled by 20674516.13% in 2022.
  • AVITA Medical's Cash from Financing Activities (Quarter) stood at $3000.0 in 2021, then surged by 29866.67% to $899000.0 in 2022, then surged by 4286.21% to $39.4 million in 2023, then plummeted by 97.41% to $1.0 million in 2024, then plummeted by 75.71% to $248000.0 in 2025.
  • Its Cash from Financing Activities was $248000.0 in Q4 2025, compared to $13.8 million in Q3 2025 and $559000.0 in Q2 2025.